Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CCXI
Churchill Capital Corp XI
$10.26
-0.1%
$0.00
$10.07
$11.00
$3.71B1.2219,561 shs6,055 shs
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$864.97
+0.6%
$918.36
$637.21
$1,034.96
$108.48B1.18808,136 shs732,948 shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$4.33
-3.8%
$4.08
$0.75
$5.54
$283.51M1.11534,240 shs219,193 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CCXI
Churchill Capital Corp XI
-0.18%+0.20%-0.29%+1,025,999,900.00%+1,025,999,900.00%
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
+0.78%-1.76%-11.03%-15.39%+30.70%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-3.78%-3.13%-6.28%+55.76%+373.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CCXI
Churchill Capital Corp XI
$10.26
-0.1%
$0.00
$10.07
$11.00
$3.71B1.2219,561 shs6,055 shs
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$864.97
+0.6%
$918.36
$637.21
$1,034.96
$108.48B1.18808,136 shs732,948 shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$4.33
-3.8%
$4.08
$0.75
$5.54
$283.51M1.11534,240 shs219,193 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CCXI
Churchill Capital Corp XI
-0.18%+0.20%-0.29%+1,025,999,900.00%+1,025,999,900.00%
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
+0.78%-1.76%-11.03%-15.39%+30.70%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-3.78%-3.13%-6.28%+55.76%+373.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CCXI
Churchill Capital Corp XI
1.00
SellN/AN/A
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
2.81
Moderate Buy$1,022.3018.19% Upside
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
2.40
Hold$7.6777.06% Upside

Current Analyst Ratings Breakdown

Latest PRLD, CCXI, and PH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/11/2026
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Set Price Target$1,064.00
5/7/2026
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Lower Price TargetOverweight$1,100.00 ➝ $1,060.00
5/6/2026
CCXI
Churchill Capital Corp XI
Initiated CoverageSell (E)
5/4/2026
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
Initiated CoverageBuy$9.00
5/1/2026
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
UpgradeSell (E+)Sell (D-)
5/1/2026
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Set Price Target$1,147.00
5/1/2026
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Set Price Target$1,050.00
5/1/2026
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Boost Price TargetBuy$1,137.00 ➝ $1,141.00
4/28/2026
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
UpgradeHold
4/27/2026
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
Boost Price TargetBuy$5.00 ➝ $8.00
4/21/2026
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Reiterated RatingBuy (B)
(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CCXI
Churchill Capital Corp XI
$37.20M19.68N/AN/AN/A
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$19.85B5.50$35.18 per share24.59$115.81 per share7.47
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$12.14M22.47N/AN/A$0.96 per share4.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CCXI
Churchill Capital Corp XI
N/A-$1.89N/AN/AN/AN/AN/AN/AN/A
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$3.53B$27.1131.9125.432.5016.58%27.97%13.00%8/6/2026 (Estimated)
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$99.50M-$1.00N/AN/AN/AN/A-118.24%-66.12%N/A

Latest PRLD, CCXI, and PH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.27-$0.13+$0.14-$0.13$4.58 million$4.58 million
4/30/2026Q3 2026
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$7.84$8.17+$0.33$7.06$5.40 billion$5.49 billion
3/10/2026Q4 2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.33-$0.20+$0.13-$0.20$20.50 million$5.64 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CCXI
Churchill Capital Corp XI
N/AN/AN/AN/AN/A
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$8.000.92%+13.70%29.51%70 Years
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/AN/AN/AN/AN/A

Latest PRLD, CCXI, and PH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2026
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
quarterly$2.000.91%5/8/20265/8/20266/5/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CCXI
Churchill Capital Corp XI
N/AN/AN/A
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
0.46
1.13
0.66
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/A
2.03
2.03

Institutional Ownership

CompanyInstitutional Ownership
CCXI
Churchill Capital Corp XI
81.09%
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
82.44%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
79.72%

Insider Ownership

CompanyInsider Ownership
CCXI
Churchill Capital Corp XI
8.30%
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
0.32%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
49.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
CCXI
Churchill Capital Corp XI
N/A71.36 millionN/AN/A
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
57,950126.22 million125.81 millionOptionable
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
12063.00 million32.01 millionOptionable

Recent News About These Companies

9 Best Biotech Penny Stocks to Buy in 2026

New MarketBeat Followers Over Time

Media Sentiment Over Time

Churchill Capital Corp XI NASDAQ:CCXI

$10.26 -0.01 (-0.10%)
Closing price 05/21/2026 03:16 PM Eastern
Extended Trading
$10.26 0.00 (0.00%)
As of 05/21/2026 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Churchill Capital Corp XI is a blank check company.

Parker-Hannifin stock logo

Parker-Hannifin NYSE:PH

$864.97 +5.53 (+0.64%)
Closing price 05/21/2026 03:59 PM Eastern
Extended Trading
$865.00 +0.03 (+0.00%)
As of 05/21/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Parker-Hannifin Corporation manufactures and sells motion and control technologies and systems for various mobile, industrial, and aerospace markets worldwide. The company operates through two segments: Diversified Industrial and Aerospace Systems. The Diversified Industrial segment offers sealing, shielding, thermal products and systems, adhesives, coatings, and noise vibration and harshness solutions; filters, systems, and diagnostics solutions to ensure purity and remove contaminants from fuel, air, oil, water, and other liquids and gases; connectors used in fluid and gas handling; and hydraulic, pneumatic, and electromechanical components and systems for builders and users of mobile and industrial machinery and equipment. This segment sells its products to original equipment manufacturers (OEMs) and distributors who serve the replacement markets in manufacturing, packaging, processing, transportation, construction, refrigeration and air conditioning, agricultural, and military machinery and equipment industries. The Aerospace Systems segment offers products for use in commercial and military airframe and engine programs, such as control actuation systems and components, engine build-up ducting, engine exhaust nozzles and assemblies, engine systems and components, fluid conveyance systems and components, fuel systems and components, fuel tank inerting systems, hydraulic systems and components, lubrication components, avionics, sensors, pneumatic control components, thermal management products, fire detection and suppression systems and components, and wheels and brakes, as well as fluid metering, delivery, and atomization devices. This segment markets its products directly to OEMs and end users. The company markets its products through direct-sales employees, independent distributors, and sales representatives. Parker-Hannifin Corporation was founded in 1917 and is headquartered in Cleveland, Ohio.

Prelude Therapeutics stock logo

Prelude Therapeutics NASDAQ:PRLD

$4.33 -0.17 (-3.78%)
Closing price 05/21/2026 04:00 PM Eastern
Extended Trading
$4.58 +0.25 (+5.66%)
As of 05/21/2026 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.